We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Coalition to Strengthen the Future of Molecular Diagnostics

By LabMedica International staff writers
Posted on 02 Jul 2013
A diverse group of stakeholders across healthcare industries and patient advocacy organizations has formed a Coalition to Strengthen the Future of Molecular Diagnostics (CSFMD). More...
Clinical labs, cancer patient-advocacy organizations, and pharmaceutical companies that manufacture medicines to treat cancer and other conditions are part of the coalition.

The purpose of the coalition is to advance and support sustainable Medicare pricing for novel precision diagnostic testing. The below cost reimbursement for molecular diagnostics observed today results directly from the recent plummet in Medicare pricing for molecular diagnostic testing.

The objective of the coalition is to inform policy makers and the Centers for Medicare and Medicaid Services (CMS, Baltimore County, MD, USA) about the value of genetic testing and the impact timely and accurate diagnosis has on treatment decisions and patient outcomes. The coalition supports CMS’ decision for more transparency and a new more efficient pricing methodology, but is concerned about the process by which newly proposed interim pricing was determined and accepted.

Molecular diagnostic testing can determine, by identifying specific genetic mutations, which therapy an individual’s cancer or disease is more likely to respond to and start the patient on the appropriate treatment immediately. These tests are eliminating trial and error treatments that waste valuable healthcare dollars and cost cancer patients precious time, as well as dramatically increase life longevity and quality of care for many patients.

Prior to 2013, molecular diagnostic tests were reimbursed through a method known as “code stacking,” where each step or process used to perform a test was billed and reimbursed. CMS announced it would restructure the current reimbursement process, and assigned individual CPT codes to more than 100 existing tests. During these ongoing deliberations aimed at determining a permanent pricing structure for 2014, interim pricing, derived by the Medicare Administrative Contractors (MACs) from a seldom used pricing method known as gap-fill, for diagnostic testing was posted by CMS and effectively cut payment rates for many critical tests, by an average of about 20 % (and as high as 80% in some cases) from 2012 levels.

In an opinion editorial published on May 23, in a congressional newspaper the Hill author Randall Oyer, MD, Medical Director of the oncology program at Lancaster Hospital in Lancaster, PA, cautioned, “If labs conducting molecular diagnostic testing have to close or offer inferior testing due to Medicare reimbursement rates well below the cost of testing itself, pharmaceutical companies will have little incentive to continue research, development and bring to clinical trials cancer therapies with no ‘companion diagnostic.’ Such a potentially dangerous domino effect could compromise innovation, tie the hands of the physician, and turn a dream come true for the cancer patient into a nightmare.”

Related Links:
Centers for Medicare and Medicaid Services


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.